RESPECT Heart Failure- RESpiratory Pattern Evaluation in Clinical Trials for HF

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2022-10-31

Study Completion Date

2022-10-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal is to evaluate the trends in MouthLab parameters (respiration rate, temperature, pulse rate, electrocardiogram rhythm, blood pressure, oxygen saturation heart rate and basic lung function measures) in patients with decompensated heart failure and how these measurements change in response to decongestion. The research will test the ability of the MouthLab device to predict clinical decompensation in patients with known heart failure and to reduce the number of hospital readmissions based on the treatment guided by MouthLab device data.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comprehensive Medication Monitoring on Heart Failure Patient Outcomes

NCT03519477

Heart Failure，Congestive

WITHDRAWN NA

Pathophysiological Mechanisms of Activity-Related Dyspnea in Heart Failure: A Pilot Study

NCT02007486

Heart Failure

UNKNOWN

Evaluating Mobile Health Tool Use for Capturing Patient-centered Outcomes Measures in HF Patients

NCT04191356

Heart Failure

TERMINATED

Monitoring Community Trends in Heart Failure

NCT00035724

Cardiovascular Diseases Heart Failure, Congestive Heart Diseases

COMPLETED

A Clinical Follow-up Study of Heart Failure Patients.

NCT03797742

Heart Failure

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Heart failure (HF) is becoming increasingly recognized with an estimated worldwide prevalence of \>37.7 million individuals. In the United States alone, there are over 5 million patients with HF which is expected to increase to over 8 million by 2030. Despite advances in medical therapies and technology, HF remains the leading cause of hospitalization among adults and the elderly. By 2030, the medical costs of HF are expected to rise from $20.9 billion to $53.1 billion, with nearly 80% of the projected increased expenses attributes to hospitalization costs. As such, it is imperative to develop new technologies and treatment options to impact the HF epidemic.

The majority of HF hospital admissions are due to volume overload. Stiffened and/or weakened myocardium predisposes patients to the accumulation of extracellular fluid resulting in increased intracardiac filling pressures and symptoms of congestion (edema, dyspnea and orthopnea). Accurate assessment of a patient's volume status remains clinically challenging at times. While there have been technological advances in the outpatient monitoring of volume status through thoracic impedance and pulmonary artery pressure monitoring, there are no validated, non-implantable options for monitoring volume status outside of the physical exam.

Aidar Health's MouthLab device is a non-invasive, hand-held, home monitoring tool that measures multiple medical parameters such as - Temperature, Blood Pressure, Heart Rate, Heart Rate Variability, Pulse Rate, SpO2, single-lead ECG, Respiratory Rate, Breathing Pattern/Respiratory Flow Cycle Morphology, and basic lung functions (FEV1, FVC, FEV1/FVC, PEF) in 30 seconds.

The investigators believe that the MouthLab device holds the potential to identify changes in volume status through measurements such as pulse rate, oxygen saturation, respiratory flow and lung function and accurately predict decompensation in patients with chronic HF. The investigators propose the following outline of clinical studies to evaluate the utility of the MouthLab device in HF.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1

Stable outpatients without implantable devices

Group Type OTHER

MouthLab Device

Intervention Type OTHER

Use of MouthLab system

Cohort 2

Stable outpatients with Boston Scientific pacemakers or defibrillators with Heart Logic capability

Group Type OTHER

MouthLab Device

Intervention Type OTHER

Use of MouthLab system

Cohort 3

Stable outpatients with implantable CardioMEMS devices

Group Type OTHER

MouthLab Device

Intervention Type OTHER

Use of MouthLab system

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MouthLab Device

Use of MouthLab system

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Adults aged ≥ 18 years old
2. Willing and able to provide informed consent
3. Admitted within previous 24 hours with HF exacerbation requiring intravenous diuretic therapy (reduced or preserved ejection fraction)
4. English speaking

1. Adults aged ≥ 18 years old
2. Willing and able to provide informed consent
3. Patients presenting to the clinic and not being admitted to the hospital, who have been admitted for a HF exacerbation within the past 6 months, OR patients being discharged from a HF exacerbation related inpatient hospitalization
4. For inclusion in Cohort 2, patients must have Boston Scientific pacemaker or defibrillator with Heart Logic capability
5. For inclusion in Cohort 3, patients must have implantable CardioMEMS device
6. Patients currently on inotropes
7. English speaking

Exclusion Criteria

1. Currently on dialysis
2. Patients with acute coronary syndrome
3. Currently on hospice
4. Have a heart transplant or left ventricular assist device

* Outpatient Sub-Study Eligibility Criteria

1. Currently on dialysis
2. Currently on hospice
3. Have a heart transplant or left ventricular assist device

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No